Jesse Swift, MD
Ophthalmology · South Ogden, UTNPI 1235491994
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,661 of the $3,293 with a category attached, or 80.8%. 23 manufacturers reported payments, led by Alcon at 40.2% of the total. Reporting peaked in 2019 at $1,478 and has fallen 57.8% since, to $624 in 2025.
Across 99 payments — averaging $33.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$402
- Apellis Pharmaceuticals, Inc.$234
- Genentech USA, Inc.$219
- Bausch & Lomb Americas Inc.$164
- Dompe US, Inc.$158
- plus $792 from 17 others
What the payments were for
- Travel & lodging$63219%
- Food & beverage$2,66181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 21 | $1,324 |
| AbbVie(2 entities) | 16 | $402 |
| Apellis Pharmaceuticals, Inc. | 6 | $234 |
| Genentech USA, Inc. | 9 | $219 |
| Bausch & Lomb Americas Inc. | 9 | $164 |
| Dompe US, Inc. | 2 | $158 |
| Regeneron Healthcare Solutions, Inc. | 6 | $156 |
| Amgen(2 entities) | 5 | $94 |
| Shire North American Group Inc | 4 | $67 |
| Astellas Pharma US Inc | 3 | $63 |
| NEW World Medical,inc. | 1 | $59 |
| Rxsight Inc | 1 | $56 |
| Sun Pharmaceutical Industries Inc. | 2 | $39 |
| Harrow Eye, LLC | 2 | $37 |
| Tarsus Pharmaceuticals, Inc. | 2 | $34 |
| Novartis | 2 | $33 |
| Ivantis, Inc | 1 | $32 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $28 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,293 in reported general payments places this provider in the 75th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 21 | $21,448 |
| LumiganBimatoprost | 13 | $8,502 |
| Loteprednol Etabonate | 20 | $3,070 |
| Prednisolone Acetate | 34 | $2,103 |
| Timolol Maleate | 77 | $1,111 |
| MoxifloxacinMoxifloxacin Hcl | 40 | $821 |
| ValacyclovirValacyclovir Hcl | 21 | $598 |
| Brimonidine Tartrate | 26 | $412 |
| Latanoprost | 47 | $410 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $251 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $402 | $29,94934 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $14 | $3,07020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in South Ogden
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Ron LordSt. George$61K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Phillip HoopesDraper$26K
- Sharon RichensSt George$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.